Collate Raises $95M to Transform Life Sciences AI

Collate, founded in 2024 by Surbhi Sarna and Nate Smith, has secured $95 million in funding, pushing its valuation to nearly $1 billion. The round was led by Redpoint Ventures, with additional support from First Round Capital and Conviction Partners. The company now has $125 million in total funding raised in under a year and a half, positioning itself as a leader in AI-driven life sciences solutions. The startup targets the overwhelming documentation burden in pharmaceuticals, medical devices, and biotech, where regulatory submissions often exceed 10,000 pages. Collate’s AI platform, tailored to medical jargon and global regulatory standards, cuts document processing time by 50-90%, completing tasks that previously took months in under a week. Accuracy rates of 90-97% are achieved through specialized LLMs, with all submissions requiring final human verification before submission to bodies like the FDA. Since its first commercial client in May 2025, Collate has grown to 50 enterprise customers, including global pharmaceutical firms and biotech startups. The new funding will accelerate scaling to meet demand, with plans to expand workflow integrations and enhance regulatory compliance tools. Sarna, a former Y Combinator partner, emphasized the strategic importance of AI in life sciences, comparing its potential impact to the rise of legal tech platforms. The company’s focus on patient safety and precision aligns with industry needs, as firms seek efficient yet reliable alternatives to building in-house AI solutions. Collate’s approach combines speed with strict accuracy controls, addressing a critical pain point in drug and device development. The funding round underscores growing venture capital interest in specialized AI applications beyond generic productivity tools.